Since adult malignancies showed a good response to a combination of PD-L1 and CTLA-4 inhibition, a recently completed pediatric phase I/II trial (NCT02304458) combined ipilimumab and nivolumab to treat R/R sarcomas and included R/R NB. This evidence concerns the gene CTLA4 and sarcoma.